Use of Name, Logo and Trademarks Sample Clauses

Use of Name, Logo and Trademarks. No party hereto shall use the other party’s/parties’ or its Affiliates’ name(s), logo(s), trademark(s), physical likeness, employee name, owner symbol, or other image in any press release, advertising or other form of publicity without prior written consent of the other party/parties, except as otherwise required by Applicable Law. Sponsor may use the Institution’s and/or Investigator’s name and other information in Trial publications and communications, including clinical trial websites and Trial newsletters, applications or forms, or other materials submitted to any regulatory authority and/or other disclosures required by Applicable Law such as disclosures in clinical trial registries. 8.2.2 Použití jména, loga a ochranných známek. Žádná ze stran této Smlouvy nesmí použít jména, loga, ochranné známky, podobenky, jména zaměstnanců, symboly vlastnictví xxxx xxxx vyobrazení ostatních stran v žádném tiskovém oznámení, reklamě nebo jiné formě publicity bez předchozího písemného souhlasu takových jiných stran, pokud Příslušné právní předpisy nestanoví jinak. Zadavatel může užívat název Zdravotnického zařízení a/nebo Zkoušejícího a informace o nich v publikacích a sděleních o Klinickém hodnocení, včetně webových stránek o klinických hodnoceních, bulletinu o Klinickém hodnocení, v žádostech, formulářích a v jiných materiálech předkládaných jakémukoli regulačnímu orgánu a/nebo v jiných materiálech zveřejňovaných dle Příslušných právních předpisů, například xxx xxxxxxxxxxxx x xxxxxxxxxx xxxxxxxxxx hodnocení.
Sample 1
AutoNDA by SimpleDocs
Use of Name, Logo and Trademarks. [specify]
Sample 1
Use of Name, Logo and Trademarks. No party hereto shall use the other party’s/parties’ or its Affiliates’ name(s),
Sample 1
Use of Name, Logo and Trademarks. No party hereto shall use the other party’s/parties’ or its Affiliates’ name(s), logo(s), trademark(s), physical likeness, employee name, owner symbol, or other image in any press release, advertising or other form of publicity without prior written consent of the other party/parties, except as otherwise required by Applicable Law. Sponsor may use the Institution’s and/or Investigator’s name and other information in Trial publications and communications, including clinical trial websites and Trial newsletters, applications or forms, or other materials submitted to any regulatory authority and/or other disclosures required by Applicable Law such as disclosures in clinical trial registries. provádění klinického hodnocení, budou mít Poskytovatel a Zkoušející právo publikovat a prezentovat výsledky své činnosti vykonávané dle této Smlouvy, včetně Výsledků, které vytvořili a jimiž přispěli, s výhradou revize a připomínek dle předchozího odstavce.
Sample 1
Use of Name, Logo and Trademarks. No party hereto shall use the other party’s/parties’ or its Affiliates’ name(s), logo(s), trademark(s), physical likeness, employee name, owner symbol, or other image in any press release, advertising or other form of publicity without prior written consent of the other party/parties, except as otherwise required by Applicable Law. Sponsor may use the Provider’s and/or Investigator’s name and other information in Trial publications and communications, including clinical trial websites and Trial newsletters, applications or forms, or other materials submitted to any regulatory authority and/or other disclosures required by Applicable Law such as disclosures in clinical trial registries.
Sample 1

Related to Use of Name, Logo and Trademarks

  • USE OF NAMES AND TRADEMARKS 9.1 Nothing contained in this Agreement confers any right to use in advertising, publicity, or other promotional activities any name, trade name, trademark, or other designation of either party hereto (including contraction, abbreviation or simulation of any of the foregoing). Unless required by law, the use by LICENSEE of the name, “The Regents Of The University Of California” or the name of any campus of the University Of California is prohibited, without the express written consent of UNIVERSITY.

  • Publicity/Use of Names Neither Party shall use the name, trademark, trade name or logo of the other Party, its Affiliates or their respective employee(s) in any publicity, promotion, news release or disclosure relating to this Agreement or its subject matter, without the prior express written permission of the other Party, except for those disclosures expressly authorized under this Article 4. Following execution of this Agreement, either Party may issue a press release announcing the existence of this Agreement in form and substance agreed to in writing by both Parties, such agreement to not be unreasonably withheld or delayed. Each Party agrees not to issue any other press release or other public statement disclosing other information relating to this Agreement or the transactions contemplated hereby without the prior written consent of the other Party, which consent shall not be unreasonably withheld or delayed; provided that Arvinas agrees that it shall be deemed reasonable for Pfizer to withhold its consent for the disclosure of any information related to a Target or a specific Compound or the amount of any payment made or to be made under this Agreement; and provided further that any disclosure which is required by Law or the rules of a securities exchange, as reasonably advised by the disclosing Party’s counsel, may be made subject to the following. Each Party agrees to provide to the other Party a copy of any public announcement regarding this Agreement or the subject matter thereof as soon as reasonably practicable under the circumstances prior to its scheduled release. Except under extraordinary circumstances or to the extent any such advance notice or notice period is not consistent with applicable Law, each Party shall provide the other with an advance copy of any such announcement at least [**] prior to its scheduled release. Each Party shall have the right to expeditiously review and recommend changes to any such announcement and, except as otherwise required by Law, the Party whose announcement has been reviewed shall remove any information the reviewing Party reasonably deems to be inappropriate for disclosure. The contents of any announcement or similar publicity which has been reviewed and approved by the reviewing Party can be re-released by either Party without a requirement for re-approval. In addition, except to the extent required by Laws in connection with patent enforcement activities conducted in accordance with Article 7, Pfizer shall not use the name “Yale” or “Yale University,” nor any variation or adaptation thereof, nor any trademark, trade name or other designation owned by Yale University, nor the names of any of its trustees, officers, faculty, students, employees or agents, for any purpose without the prior written consent of Yale University in each instance, such consent to be granted or withheld by Yale University in its sole discretion, except that Pfizer may state that it has sublicensed from Yale University one or more of the patents or applications comprising the Yale Licensed Patents.

  • Use of Names The Manager and the Fund agree that the Manager has a proprietary interest in the names “DFA” and “Dimensional,” and that the Fund and/or Portfolio may use such names only as permitted by the Manager, and the Fund further agrees to cease use of such names promptly after receipt of a written request to do so from the Manager.

  • Trade Names and Trademarks No Issuer Entity may use any company name, trade name, trademark or service xxxx or logo of Ameriprise or any person or entity controlling, controlled by, or under common control with Ameriprise without Ameriprise’s prior written consent.

  • Use of Names; Publicity The Trust shall not use the Distributor’s name in any offering material, shareholder report, advertisement or other material relating to the Trust, other than for the purpose of merely identifying and describing the functions of the Distributor hereunder, in a manner not approved by the Distributor in writing prior to such use, such approval not to be unreasonably withheld. The Distributor hereby consents to all uses of its name required by the SEC, any state securities commission, or any federal or state regulatory authority. The Distributor shall not use the name “Tidal ETF Trust” in any offering material, shareholder report, advertisement or other material relating to the Distributor, other than for the purpose of merely identifying the Trust as a client of Distributor hereunder, in a manner not approved by the Trust in writing prior to such use; provided, however, that the Trust shall consent to all uses of its name required by the SEC, any state securities commission, or any federal or state regulatory authority; and provided, further, that in no case shall such approval be unreasonably withheld. The Distributor will not issue any press releases or make any public announcements regarding the existence of this Agreement without the express written consent of the Trust. Neither the Trust nor the Distributor will disclose any of the economic terms of this Agreement, except as may be required by law.

  • Use of Name (a) The Sub-Adviser hereby consents to the use of its name and the names of its affiliates in the Fund’s disclosure documents, shareholder communications, advertising, sales literature and similar communications. The Sub-Adviser shall not use the name or any tradename, trademark, trade device, service xxxx, symbol or any abbreviation, contraction or simulation thereof of the Adviser, the Trust, the Fund or any of their affiliates in its marketing materials unless it first receives prior written approval of the Trust and the Adviser.

  • Patents and Trademarks The Company and the Subsidiaries have, or have rights to use, all patents, patent applications, trademarks, trademark applications, service marks, trade names, trade secrets, inventions, copyrights, licenses and other intellectual property rights and similar rights necessary or material for use in connection with their respective businesses as described in the SEC Reports and which the failure to so have could have a Material Adverse Effect (collectively, the “Intellectual Property Rights”). Neither the Company nor any Subsidiary has received a notice (written or otherwise) that any of the Intellectual Property Rights used by the Company or any Subsidiary violates or infringes upon the rights of any Person. To the knowledge of the Company, all such Intellectual Property Rights are enforceable and there is no existing infringement by another Person of any of the Intellectual Property Rights. The Company and its Subsidiaries have taken reasonable security measures to protect the secrecy, confidentiality and value of all of their intellectual properties, except where failure to do so could not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.

  • Use of Trademarks Subject to the terms and conditions hereof, Sponsor hereby represents and warrants that it has the power and authority to grant, and does hereby grant to Show Management a non-exclusive, nontrans- ferable, royalty-free, worldwide license to reproduce and display all logos, trademarks, trade names and similar identifying material relating to Sponsor (the ”Sponsor Marks”) solely in connection with the promotion, marketing and distribution of the parties in accordance with the terms hereof, provided, however, that Show Management shall, other than as specifically provided for in this Agreement, not make any specific use of any Sponsor Mark without first submitting a sample of such use to Spon- sor and obtaining its prior consent, which consent shall not be unreasonably withheld. The foregoing license shall terminate upon the effective date of expiration of this Agreement.

  • Trademarks and Trade Names Except as specifically set out in this Agreement, nothing in this Agreement shall grant, suggest, or imply any authority for one Party to use the name, trademarks, service marks, or trade names of the other for any purpose whatsoever.

Time is Money Join Law Insider Premium to draft better contracts faster.